Metastat Inc. (MTST)

Overview

MetaStat, Inc. is a precision medicine company deeply engaged in the battle against cancer, with a focus on creating and commercializing innovative therapeutic and diagnostic treatments for cancer patients. Operating from its headquarters in Boston, Massachusetts, MetaStat is steering efforts towards pioneering novel drug candidates and companion diagnostic tests specifically targeting the MENA pathway, a significant landmark in the quest to combat metastasis and tumor resistance in solid tumors. By delving into the intricate biological mechanisms that underpin cancer's spread and resistance to treatment, MetaStat positions itself at the forefront of precision oncology, aiming to considerably enhance patient outcomes through personalized medicine approaches.

Products and Services

MetaStat, Inc. offers a diverse portfolio of products and services designed to advance cancer diagnosis and treatment, including:

• MENA Diagnostic Assay: A tissue-based quantitative immunofluorescence assay that quantitatively measures the expression of the MENA protein splice-variant, a known pro-metastatic factor. This diagnostic tool plays a pivotal role in assessing tumor aggressiveness and the potential for metastasis.
• Companion Diagnostics: These diagnostics are crucial for predicting patient responses to specific cancer treatments, including RTK inhibitor drugs and anti-microtubule drugs. By identifying patients most likely to benefit from these treatments, these companion diagnostics facilitate more personalized and effective treatment strategies.
• Liquid Blood-based Biopsy: An innovative approach to cancer diagnosis and patient care optimization, this liquid biopsy makes it possible to detect and treat cancer more efficiently by analyzing circulating tumor DNA in blood samples. This non-invasive method represents a significant advancement in early cancer detection and monitoring.
• MetaSite Breast Assay: An immunohistochemistry test designed to measure the micro-anatomical sites within the tumor microenvironment, specifically the blood vessels where invasive cancer cells are most likely to enter the circulation and form metastases. This assay helps in assessing the risk of breast cancer metastasis.
• Prognostic Diagnostic: Aimed at predicting the risk of cancer metastasis, this prognostic tool is tailored to identify patients at high risk for aggressive cancer spread, thereby guiding treatment decisions and potentially improving clinical outcomes.

Moreover, the company's therapeutic research targets a crucial metastatic pathway within solid tumors, focusing on strategies to limit tumor resistance and prevent the spread of aggressive cancer forms. Through these efforts, MetaStat endeavors to bring groundbreaking solutions to the oncology field, significantly impacting patient care and treatment paradigms.